Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Number of shares composing the share capital
Theoretical number of voting rights
August 31, 2021
(1) Including 2,595,000 shares issued from the equity line financing with Kepler Cheuvreux announced on November 19th 2019 and 974,429 shares issued from the convertible bond program announced on February 4, 2021 and terminated on June 7, 2021.
(2) This table will be subject to a monthly update of the number of shares issued from the convertible bond program announced on June 7, 2021 with Global Tech Opportunities 13 , and detailed in follow-up tables available on the website https://equityline.vox-aequitas.com/pharnext
Euronext Growth Paris
ALPHA/FR – Reuters: ALPHA.PA
First day of trading
18 July 2016
Number of shares
See table above
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Eligible to PEA-PME (French fiscal advantage)
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Initiation of coverage report*
R&D Day Event report*
Report on PREMIER trial initiation*
Report on the Open-Label Phase III Extension Study of PXT3003*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Find here the recording of the webcast during which our CEO and CMO presented and discussed the results of an interim analysis of our PXT3003 open-label Phase III Extension study
Pharnext will attend the AANEM 2021 Annual Meeting to be held in Aurora, Colorado (US)
Pharnext will attend the RARE 2021 Annual Meeting which is going virtual
Presentation of the PLEO-CMT-FU extension study update
Recording of the webcast presentation of the PLEO-CMT-FU extension study update
Presentation of the R&D Day Event
Highlights of the R&D Day Event
Letter to shareholders
46 Rue Saint-Lazare
75009 Paris, France
+33 (0)1 41 09 22 email@example.com